Rathbones Group’s AstraZeneca AZN Stock Holding History

Rathbones Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49B	Sell	7,979,150 -75,793	-0.9%	-$14.3M	5.5%	1
2026 Q1	$1.56B	Buy	8,054,943 +8,051,174	+213,616%	+$1.55B	6.23%	1
2025 Q4	$693K	Sell	3,769 -2,100	-36%	-$368K	﹤0.01%	408
2025 Q3	$900K	Hold	5,869	–	–	﹤0.01%	362
2025 Q2	$820K	Sell	5,869 -127	-2%	-$17.8K	﹤0.01%	361
2025 Q1	$881K	Hold	5,996	–	–	﹤0.01%	340
2024 Q4	$786K	Sell	5,996 -856	-12%	-$120K	﹤0.01%	358
2024 Q3	$1.07M	Buy	6,852 +113	+2%	+$18.2K	0.01%	326
2024 Q2	$1.05M	Hold	6,739	–	–	0.01%	325
2024 Q1	$913K	Hold	6,739	–	–	0.01%	340
2023 Q4	$908K	Hold	6,739	–	–	0.01%	327
2023 Q3	$913K	Buy	+6,739	New	+$920K	0.01%	329

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rathbones Group's AZN Position: Q2 2026 in Review

Rathbones Group reduced its AstraZeneca (AZN) stake by 0.94% in Q2 2026, selling an estimated $14.3M and leaving 7,979,150 shares worth $1.49B. The position accounts for 5.5% of the portfolio, ranked #1.

Rathbones Group first reported a position in AZN in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.56B in Q1 2026. 1,501 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Rathbones Group held 7,979,150 shares of AstraZeneca worth $1.49B as of Q2 2026.
Rathbones Group sold 75,793 AstraZeneca shares in Q2 2026, an estimated $14.3M.
AstraZeneca made up 5.5% of Rathbones Group's portfolio in Q2 2026, its #1 holding.
Rathbones Group first reported a position in AstraZeneca in Q3 2023 and has held it in 12 quarters since.
Rathbones Group's AstraZeneca position peaked at $1.56B in Q1 2026.
1,501 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.